Vaxcyte: Sentiment Is Pushing The Shares Down
Source: SeekingAlpha
2025-06-10 13:57:41 ET
Today, I am putting Vaxcyte, Inc. ( PCVX ) in the spotlight for the first time since late 2023. I concluded my last article on this clinical stage vaccine stating the shares looked " fully valued" and declined any investment recommendation around the shares. The stock has dropped approximately 40% since then, prompting a revisit. An updated analysis follows below....
Read the full article on Seeking Alpha
For further details see:
Vaxcyte: Sentiment Is Pushing The Shares Down
Vaxcyte Inc.
NASDAQ: PCVX
PCVX Trading
-5.27% G/L:
$56.345 Last:
137,057 Volume:
$58.62 Open:
PCVX Latest News
February 24, 2026 04:05:00 pm
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 11, 2026 04:05:00 pm
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
February 10, 2026 04:05:00 pm
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
PCVX Stock Data
$7,801,730,421
136,657,209
0.01%
97
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
